Target intelligence / Profile preview

Negative regulator of P-body association (NBDY)

Target
NBDY
Molecular classification
Other (microprotein encoded by a small open reading frame within a lncRNA), Long noncoding RNA product
01

Overview

Negative regulator of P-body association (NBDY), commonly known as NoBody or LINC01420 microprotein, is a ~7 kDa mammalian microprotein translated from a small open reading frame within the first exon of the long noncoding RNA gene LINC01420 (LOC550643)[1][2]. NBDY directly interacts with mRNA decapping proteins such as EDC4, Dcp1A/B, and Dcp2, which are central components of the 5'-to-3' mRNA decay pathway. Manipulation of NBDY levels in cells inversely correlates with the number of cytoplasmic P-bodies—organelles involved in mRNA turnover—indicating that NBDY is a functional component of the mRNA decapping complex[1]. NBDY itself is required for P-body dispersal, and its silencing increases P-body number, demonstrating its role as a negative regulator. Expression of LINC01420 and its microprotein product is broadly conserved among mammals, often exhibiting housekeeping features. In cancer cell models, LINC01420 and/or NBDY have been associated with regulation of cell migration, with reported context-dependent effects. There is currently no evidence of therapeutic targeting or known drug interactions involving NBDY[1][2]. Biological functions likely center on mRNA metabolism; potential disease roles (such as in cancer) are under active investigation.

Other names
NoBodyLINC01420P-body dissociating proteinnon-annotated P-body dissociating polypeptidelong intergenic non-protein coding RNA 1420LOC550643Protein NoBodyNBDY
02

Biological functions

Modulation of P-body formationInteraction with mRNA decapping proteins (e.g., EDC4, Dcp1A, Dcp1B, Dcp2)Involvement in mRNA decay and nonsense-mediated decayPotential regulation of cell migration (cell context-specific)
03

Disease associations

Observed roles in cancer cell migration and metastasis (context-specific, e.g., nasopharyngeal carcinoma)[2]Additional roles remain unclear; more research needed

Beyond the preview

Go deeper on Negative regulator of P-body association (NBDY).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Negative regulator of P-body association (NBDY).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call